Manu Rangachari

Dr. Manu Rangachari


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
Simon ZhornitskySimon Zhornitsky
Simon Zhornitsky
KMKyla A. McKay
Kyla A. McKay
LMLuanne M. Metz
Luanne M. Metz
CTCharlotte E. Teunissen
Charlotte E. Teunissen
MRManu Rangachari
Manu Rangachari

5 January 2019 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
ISIsabelle St-Amour
Isabelle St-Amour
CBCristina R. Bosoi
Cristina R. Bosoi
IPIsabelle Paré
Isabelle Paré
PDPrenitha Mercy Ignatius Arokia Doss
Prenitha Mercy Ignatius Arokia Doss
MRManu Rangachari
Manu Rangachari
FCFrederic Calon
Frederic Calon
Immunologic abnormalities have been described in peripheral blood and central nervous system of patients suffering from Alzheimer’s disease (AD), yet their role in the pathogenesis still remains poorly defined. We used the triple transgenic mouse model (3xTg-AD) to reproduce Aβ (amyloid plaques) and tau (neurofibrillary tangles) neuropathologies. We analyzed important features of the adaptive immune system in serum, primary (bone marrow) as well as secondary (spleen) lymphoid organs of 12-month-old 3xTg-AD mice using flow cytometry and ELISPOT. We further investigated serum cytokines of 9- and 13-month-old 3xTg-AD mice using multiplex ELISA. Results were compared to age-matched non-transgenic controls (NTg). In the bone marrow of 12-month-old 3xTg-AD mice, we detected decreased proportions of short-term reconstituting hematopoietic stem cells (0.58-fold, P = 0.0116), while lymphocyte, granulocyte, and monocyte populations remained unchanged. Our results also point to increased activation of both B and T lymphocytes. Indeed, we report elevated levels of plasma cells in bone marrow (1.3-fold, P = 0.0405) along with a 5.4-fold rise in serum IgG concentration (P < 0.0001) in 3xTg-AD animals. Furthermore, higher levels of interleukin (IL)-2 were detected in serum of 9- and 13-month-old 3xTg-AD mice (P = 0.0018). Along with increased concentrations of IL-17 (P = 0.0115) and granulocyte-macrophage colony-stimulating factor (P = 0.0085), these data support helper T lymphocyte activation with Th17 polarization. Collectively, these results suggest that the 3xTg-AD model mimics modifications of the adaptive immunity changes previously observed in human AD patients and underscore the activation of both valuable and harmful pathways of immunity in AD.

25 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
EDEtienne Doré
Etienne Doré
CJCharles Joly-Beauparlant
Charles Joly-Beauparlant
SMSatoshi Morozumi
Satoshi Morozumi
AMAlban Mathieu
Alban Mathieu
TLTania Lévesque
Tania Lévesque
EBEric Boilard
Eric Boilard
Secreted phospholipase A 2 -IIA (sPLA 2 -IIA) hydrolyzes phospholipids to liberate lysophospholipids and fatty acids. Given its poor activity toward eukaryotic cell membranes, its role in the generation of proinflammatory lipid mediators is unclear. Conversely, sPLA 2 -IIA efficiently hydrolyzes bacterial membranes. Here, we show that sPLA 2 -IIA affects the immune system by acting on the intestinal microbial flora. Using mice overexpressing transgene-driven human sPLA 2 -IIA, we found that the intestinal microbiota was critical for both induction of an immune phenotype and promotion of inflammatory arthritis. The expression of sPLA 2 -IIA led to alterations of the intestinal microbiota composition, but housing in a more stringent pathogen-free facility revealed that its expression could affect the immune system in the absence of changes to the composition of this flora. In contrast, untargeted lipidomic analysis focusing on bacteria-derived lipid mediators revealed that sPLA 2 -IIA could profoundly alter the fecal lipidome. The data suggest that a singular protein, sPLA 2 -IIA, produces systemic effects on the immune system through its activity on the microbiota and its lipidome.

1 March 2021 in Cell Reports
Verified
Journal Article
Open access
PDPrenitha Mercy Ignatius Arokia Doss
Prenitha Mercy Ignatius Arokia Doss
MUMuhammad Umair
Muhammad Umair
JBJoanie Baillargeon
Joanie Baillargeon
RFReda Fazazi
Reda Fazazi
NFNeva Fudge
Neva Fudge
MRManu Rangachari
Manu Rangachari
Sex differences in multiple sclerosis (MS) incidence and severity have long been recognized. However, the underlying cellular and molecular mechanisms for why male sex is associated with more aggressive disease remain poorly defined. Using a T cell adoptive transfer model of chronic experimental autoimmune encephalomyelitis (EAE), we find that male Th17 cells induce disease of increased severity relative to female Th17 cells, irrespective of whether transferred to male or female recipients. Throughout the disease course, a greater frequency of male Th17 cells produce IFNγ, a hallmark of pathogenic Th17 responses. Intriguingly, XY chromosomal complement increases the pathogenicity of male Th17 cells. An X-linked immune regulator, Jarid1c, is downregulated in pathogenic male murine Th17 cells, and functional experiments reveal that it represses the severity of Th17-mediated EAE. Furthermore, Jarid1c expression is downregulated in CD4+ T cells from MS-affected individuals. Our data indicate that male sex chromosomal complement critically regulates Th17 cell pathogenicity.

17 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NBNicolas Boivin
Nicolas Boivin
JBJoanie Baillargeon
Joanie Baillargeon
PDPrenitha Mercy Ignatius Arokia Doss
Prenitha Mercy Ignatius Arokia Doss
ARAndrée-Pascale Roy
Andrée-Pascale Roy
MRManu Rangachari
Manu Rangachari
Interferon (IFN)-β is a front-line therapy for the treatment of the relapsing-remitting form of multiple sclerosis. However, its immunosuppressive mechanism of function remains incompletely understood. While it has been proposed that IFN-β suppresses the function of inflammatory myelin antigen-reactive T cells by promoting the release of immunomodulatory cytokines such as IL-27 from antigen-presenting cells (APCs), its direct effects on inflammatory CD4+ Th1 cells are less clear. Here, we establish that IFN-β inhibits mouse IFN-γ+ Th1 cell function in the absence of APCs. CD4+ T cells express the type I interferon receptor, and IFN-β can suppress Th1 cell proliferation under APC-free stimulation conditions. IFN-β-treated myelin antigen-specific Th1 cells are impaired in their ability to induce severe experimental autoimmune encephalomyelitis (EAE) upon transfer to lymphocyte-deficient Rag1-/- mice. Polarized Th1 cells downregulate IFN-γ and IL-2, and upregulate the negative regulatory receptor Tim-3, when treated with IFN-β in the absence of APCs. Further, IFN-β treatment of Th1 cells upregulates phosphorylation of Stat1, and downregulates phosphorylation of Stat4. Our data indicate that IFN-γ-producing Th1 cells are directly responsive to IFN-β and point to a novel mechanism of IFN-β-mediated T cell suppression that is independent of APC-derived signals.

22 April 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MMMadison MacDougall
Madison MacDougall
JSJad El-Hajj Sleiman
Jad El-Hajj Sleiman
PBPhilippe Beauchemin
Philippe Beauchemin
MRManu Rangachari
Manu Rangachari
While the respiratory tract is the primary route of entry for SARS-CoV-2, evidence shows that the virus also impacts the central nervous system. Intriguingly, case reports have documented SARS-CoV-2 patients presenting with demyelinating lesions in the brain, spinal cord, and optic nerve, suggesting possible implications in neuroimmune disorders such as multiple sclerosis (MS) and other related neuroimmune disorders. However, the cellular mechanisms underpinning these observations remain poorly defined. The goal of this paper was to review the literature to date regarding possible links between SARS-CoV-2 infection and neuroimmune demyelinating diseases such as MS and its related disorders, with the aim of positing a hypothesis for disease exacerbation. The literature suggests that SARS-CoV, SARS-CoV-2, and orthologous murine coronaviruses invade the CNSviathe olfactory bulb, spreading to connected structuresviaretrograde transport. We hypothesize that a glial inflammatory response may contribute to damaged oligodendrocytes and blood brain barrier (BBB) breakdown, allowing a second route for CNS invasion and lymphocyte infiltration. Potential for molecular mimicry and the stimulation of autoreactive T cells against myelin is also described. It is imperative that further studies on SARS-CoV-2 neuroinvasion address the adverse effects of the virus on myelin and exacerbation of MS symptoms, as nearly 3 million people suffer from MS worldwide.